Lyra Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 145
- Market Cap
- $21.6M
Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)
- Conditions
- Chronic SinusitisChronic Rhinosinusitis (Diagnosis)
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Lyra Therapeutics
- Target Recruit Count
- 182
- Registration Number
- NCT05295459
- Locations
- 🇺🇸
Novak Clinical Trials, Tucson, Arizona, United States
🇺🇸Keck School of Medicine at USC Medical Center, Arcadia, California, United States
🇺🇸Sensa Health Clinical Research, Los Angeles, California, United States
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults
- Conditions
- Chronic SinusitisChronic Rhinosinusitis (Diagnosis)
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Lyra Therapeutics
- Target Recruit Count
- 196
- Registration Number
- NCT05219968
- Locations
- 🇪🇸
Lyra Investigational Site, Santander, Spain
LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)
- Conditions
- Chronic SinusitisChronic Rhinosinusitis (Diagnosis)
- Interventions
- Drug: LYR-220 Design 1 (Part 1 only)Drug: LYR-220 Design 2 (Part 1 and Part 2)Drug: Bilateral sham procedure control (Part 2)
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Lyra Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT05035654
- Locations
- 🇦🇺
Lyra Investigational Site, Melbourne, Australia
LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)
- Conditions
- Chronic SinusitisChronic Rhinosinusitis (Diagnosis)
- Interventions
- Other: Sham comparator
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Lyra Therapeutics
- Target Recruit Count
- 71
- Registration Number
- NCT04041609
- Locations
- 🇦🇺
Royal Brisbane and Woman's Hospital, Brisbane, Australia
🇦🇺Monash Health, Clayton, Australia
🇦🇺The ENT Centre, Hornsby, Australia
480 Biomedical Sinus Drug Depot
- Conditions
- Chronic Sinusitis
- Interventions
- Drug: 480 Mometasone Furoate Sinus Drug Depot
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Lyra Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT02967731
- Locations
- 🇦🇺
The Queen Elizabeth Hospital, Adelaide, Australia
🇦🇺Royal Brisbane and Women's Hospital, Brisbane, Australia
🇦🇺Monash Medical Center, Melbourne, Australia
News
Lyra Therapeutics Completes Enrollment in Phase 3 Trial of LYR-210 for Chronic Rhinosinusitis
Lyra Therapeutics has fully enrolled its pivotal Phase 3 ENLIGHTEN 2 trial evaluating LYR-210 for chronic rhinosinusitis (CRS) in adults without prior ethmoid sinus surgery.
Lyra Therapeutics' Phase 3 ENLIGHTEN 1 Trial for Chronic Rhinosinusitis Treatment Fails to Meet Primary Endpoint
Lyra Therapeutics announced that its Phase 3 ENLIGHTEN 1 trial evaluating LYR-210, a bioabsorbable sinonasal implant for chronic rhinosinusitis, failed to meet its primary endpoint of demonstrating statistically significant improvement in cardinal symptoms compared to sham control at 24 weeks.